Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma

Cancer Research

Volumn 65, Issue 19, 2005, Pages 8861-8868

  Wong, Chun Ming ^a   Yam, Judy Wai Ping ^a   Ching, Yick Pang ^a,b   Yau, Tai On ^a   Leung, Thomas Ho Yin ^a   Jin, Dong Yan ^b   Ng, Irene Oi Lin ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; LIPID TRANSFER PROTEIN; RHO FACTOR; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHO GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; STEROIDOGENIC ACUTE REGULATORY PROTEIN; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER INVASION; CARCINOGENICITY; CELL MOTILITY; CELL PROLIFERATION; DLC1 GENE; FEMALE; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; GENE INACTIVATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FAMILY; TUMOR SUPPRESSOR GENE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL ADHESION; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; ENZYME ACTIVATION; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; MUTAGENESIS, SITE-DIRECTED; NEOPLASM INVASIVENESS; RHO GTP-BINDING PROTEINS; TUMOR SUPPRESSOR PROTEINS;

EID: 25444499134     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-1318     Document Type: Article

References (46)

1. Chen CJ, Yu MW, Liaw YF. Epidemiological characteristics and risk factors of hepatocelJular carcinoma. J Gastroenterol Hepatol 1997;12:S294-308.
2. Chan KL, Lee JM, Guan XY, Fan ST, Ng IO. High-density allelotyping of chromosome 8p in hepatocellular carcinoma and clinicopathologic correlation. Cancer 2002;94:3179-85.
3. Marchio A, Meddeb M, Pineau P, et al. Recurrent chromosomal abnormalities in hepatocellular carcinoma detected by comparative genomic hybridization. Genes Chromosomes Cancer 1997;18:59-65.
4. Piao Z, Park C, Park JH, Kim H. Allelotype analysis of hepatocellular carcinoma. Int J Cancer 1998;75:29-33.
5. Wong CM, Lee JM, Lau TC, Fan ST, Ng IO. Clinicopathological significance of loss of heterozygosity on chromosome 13q in hepatocellular carcinoma. Clin Cancer Res 2002;8:2266-72.
6. Nagai H, Pineau P, Tiollais P, Buendia MA, Dejean A, Comprehensive allelotyping of human hepatocellular carcinoma Oncogene 1997;14:2927-33.
7. Tamura S, Nakamori S, Kuroki T, et al. Association of cumulative allelic losses with tumor aggressiveness in hepatocellular carcinoma. J Hepatol 1997;27:669-76.
8. Yuan BZ, Miller MJ, Keck CL, Zimonjic DB, Thorgeirsson SS, Popescu NC. Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res 1998;58:2196-9.
9. Chinen K, Isomura M, Izawa K, et al Isolation of 45 exon-like fragments from 8p22->p21.3, a region that is commonly deleted in hepatocellular, colorectal, and non-small cell lung carcinomas. Cytogenet Cell Genet 1996;75:190-6.
10. Wistuba II, Behrens C, Virmani AK, et al. Allelic losses at chromosome 8p21-23 are early and frequent events in the pathogenesis of lung cancer. Cancer Res 1999;59:1973-9.
11. Fujiwara Y, Ohata H, Emi M, et al. A 3-Mb physical map of the chromosome region 8p21.3-p22, including a 600-kb region commonly deleted in human hepatocellular carcinoma, colorectal cancer, and non-small cell lung cancer, Genes Chromosomes Cancer 1994;10:7-14.
12. Homma Y, Emori Y. A dual functional signal mediator showing RhoGAP and phospholipase C-δ stimulating activities. EMBO J 1995;14:286-91.
13. Sekimata M, Kabuyama Y, Emori Y, Homma Y. Morphological changes and detachment of adherent cells induced by p122, a GTPase-activating protein for Rho. J Biol Chem 1999;274:17757-62.
14. Wong CM, Lee JM, Ching YP, Jin DY, Ng IO. Genetic and epigenetic alterations of DLC-I gene in hepatocellular carcinoma Cancer Res 2003;63:7646-51.
15. Moon SY, Zheng Y. Rho GTPase-activating proteins in cell regulation. Trends Cell Biol 2003;13:13-22.
16. Peck J, Douglas Gt, Wu CH, Burbelo PD. Human RhoGAP domain-containing proteins: structure, function and evolutionary relationships. FEBS Lett 2002;528:27-34.
17. Qiu RG, Chen J, McCormick F, Symons M. A role for Rho in Ras transformation. Proc Natl Acad Sci U S A 1995;92:11781-5.
18. Qiu RG, Chen J, Kirn D, McCormick F, Symons M. An essential role for Rac in Ras transformation. Nature 1995;374:457-9.
19. Khosravi-Far R, Solski PA, Clark GJ, Kinch MS, Der CJ. Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation. Mol Cell Biol 1995;15:6443-53.
20. Qiu RG, Abo A, McCormick F, Symons M. Cdc42 regulates anchorage-independent growth and is necessary for Ras transformation. Mol Cell Biol 1997;17:3449-58.
21. Horiuchi A, Imai T, Wang C, Ohira S, Feng Y, Nikaido T, Konishi I. Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Lab Invest 2003;83:861-70.
22. Kamai T, Tsujii T, Aral K, et al. Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res 2003;9:2632-41.
23. Wang DZ, Nur EKMS, Tikoo A, Montague W, Maruta H. The GTPase and Rho GAP domains of p190, a tumor suppressor protein that binds the M(r) 120,000 Ras GAP, independently function as anti-Ras tumor suppressors. Cancer Res 1997;57:2478-84.
24. Dong R-C. Establishment of a human hepatocarcinoma cell line SMMC-7721 and initial observations on its biologic characteristics. In: Tang ZY, Wu MC, Xia SS, editors. Primary liver cancer. Berlin: Springer-Verlag; 1990. p. 145-33.
25. Hsiao WL, Gattoni-Celli S, Weinstein IB. Oncogene-induced transformation of C3H 10T1/2 cells is enhanced by tumor promoters. Science 1984;226:552-5.
26. Ng IO, Liang ZD, Cao L, Lee TK. DLC-1 is deleted in primary hepatocellular carcinoma and exerts inhibitory effects on the proliferation of hepatoma cell lines with deleted DLC-1. Cancer Res 2000;60:6581-4.
27. Terranova VP, Hujanen ES, Loeb DM, Martin GR, Thornburg L, Glushko V. Use of a reconstituted basement membrane to measure cell invasiveness and select for highly invasive tumor cells. Proc Natl Acad Sci USA 1986;83:465-9.
28. Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A. The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell 1992;70:401-10.
29. Nobes CD, Hall A. Rho, rac and cdc42 GTPases: regulators of actin structures, cell adhesion and motility. Biochem Soc Trans 1995;23:456-9.
30. Maddox AS, Burridge K. RhoA is required for cortical retraction and rigidity during mitotic cell rounding. J Cell Biol 2003;160:255-65.
31. Yuan BZ, Jefferson AM, Baldwin KT, Thorgeirsson SS, Popescu NC, Reynolds SH. DLC-I operates as a tumor suppressor gene in human non-small cell lung carcinomas. Oncogene 2004;23:1405-11.
32. Yuan BZ, Zhou X, Durkin ME, et al. DLC-1 gene inhibits human breast cancer cell growth and in vivo tumorigenicity. Oncogene 2003;22:445-50.
33. Zhou X, Thorgeirsson SS, Popescu NC. Restoration of DLC-1 gene expression induces apoptosis and inhibits both cell growth and tumorigenicity in human hepatocellular carcinoma cells. Oncogene 2004;23:1308-13.
34. Yuan BZ, Durkin ME, Popescu NC. Promoter hypermethylation of DLC-1, a candidate tumor suppressor gene, in several common human cancers. Cancer Genet Cytogenet 2003;140:113-7.
35. Park SW, Durkin ME, Thorgeirsson SS, Popescu NC. DNA variants of DLC-1, a candidate tumor suppressor gene in human hepatocellular carcinoma. Int J Oncol 2003;23:133-7.
36. Wilson PJ, McGlinn E, Marsh A, et al. Sequence variants of DLC1 in colotectal and ovarian tumours. Hum Mutat 2000;15:156-65.
37. Plaumann M, Seitz S, Frege R, Estevez-Schwarz L, Scherneck S. Analysis of DLC-1 expression in human breast cancer. J Cancer Res Clin Oncol 2003;129:349-54.
38. Kim TY, Jong HS, Song SH, et al. Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells. Oncogene 2003;22:3943-51.
39. Yoshioka K, Nakamori S, Itoh K. Overexpression of small GTP-binding protein RhoA promotes invasion of tumor cells. Cancer Res 1999;59:2004-10.
40. Hodge JC, Bub J, Kaul S, Kajdacsy-Balla A, Lindholm PF. Requirement of RhoA activity for increased nuclear factor κB activity and PC-3 human prostate cancer cell invasion. Cancer Res 2003;63:1359-64.
41. Genda T, Sakamoto M, Ichida T, et al. Cell motility mediated by rho and Rho-associated protein kinase plays a critical role in intrahepatic metastasis of human hepatocellular carcinoma. Hepatology 1999;30:1027-36.
42. Bishop AL, Hall A. Rho GTPases and their effector proteins. Biochem J 2000;348 Pt 2:241-55.
43. Amano M, Chihara K, Kimura K, et al. Formation of actin stress fibers and focal adhesions enhanced by Rho-kinase. Science 1997;275:1308-11.
44. Kimura K, Ito M, Amano M, et al. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase). Science 1996;273:245-8.
45. Sahai E, Marshall CJ. Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. Nat Cell Biol 2003;5:711-9.
46. Ponting CP, Aravind L. START: a lipid-binding domain in StAR, HD-ZIP and signalling proteins. Trends Biochem Sci 1999;24:130-2.